Aptahem submit regulatory approval to initiate clinical phase 1 study
Aptahem AB (publ) announce today that applications to the regulatory authority and the central ethics committee in The Netherlands have been submitted for approval to initiate a clinical phase 1 study with its drug candidate Apta-1.Aptahem develop Apta-1 to offer an emergency treatment to prevent the emergence of organ and tissue damage in patients suffering from sepsis or other critical inflammatory conditions. The applications to the regulatory authority, Centrale Commissie Mensgebonden Onderzoek (CCMO, and the responsible ethical committee in The Netherlands for approval to initiate a
At the moment, operators across Europe are frantically trying to find ways to reduce their dependence on fossil fuels and raw materials, and alternative raw materials are being sought in every sector. Again this summer, record-high temperatures hit various parts of Europe, reminding us of the existence of climate change and making the need to reduce carbon emissions even more pressing. In the post-pandemic world, it has become evident that the availability of goods is not a given and that reliable supply chains play an even more significant role in ensuring operational reliability.There has
